

Table S1. Summary of Body Weight and Food Intake of Sprague-Dawley Rats

| Week | Group / Dose (mg/kg/day) | | | |
|------------------------|--------------------------|--------------|--------------|--------------|
| | G1 / 0 | G2 / 1,250 | G3 / 2,500 | G4 / 5,000 |
| Body weight (g) | | | | |
| Sex : Male | | | | |
| 0 | 211.7 ± 6.7 | 210.7 ± 6.8 | 211.7 ± 6.2 | 210.5 ± 3.5 |
| 4 | 364.7 ± 31.5 | 363.5 ± 26.9 | 373.6 ± 31.5 | 360.2 ± 21.0 |
| 8 | 520.5 ± 58.0 | 513.3 ± 214 | 514.7 ± 54.9 | 507.1 ± 40.5 |
| 13 | 605.1 ± 62.9 | 595.7 ± 67.1 | 624.3 ± 61.6 | 589.7 ± 47.1 |
| Sex: Female | | | | |
| 0 | 159.6 ± 5.4 | 160.0 ± 5.8 | 159.8 ± 6.5 | 159.6 ± 8.5 |
| 4 | 227.1 ± 23.0 | 220.3 ± 9.0 | 222.8 ± 5.0 | 220.0 ± 23.8 |
| 8 | 295.3 ± 34.2 | 281.1 ± 12.4 | 282.9 ± 25.9 | 284.5 ± 32.6 |
| 13 | 336.2 ± 33.8 | 314.4 ± 19.9 | 312.9 ± 27.1 | 321.0 ± 39.3 |
| Food intake (g) | | | | |
| Sex : Male | | | | |
| 0 | 30.1 ± 2.1 | 30.0 ± 2.3 | 30.5 ± 3.3 | 29.6 ± 2.0 |
| 4 | 35.2 ± 3.6 | 36.2 ± 2.0 | 36.6 ± 4.8 | 34.8 ± 3.0 |
| 8 | 36.7 ± 3.7 | 37.1 ± 4.1 | 37.5 ± 4.0 | 35.8 ± 3.5 |
| 13 | 34.5 ± 3.4 | 34.6 ± 3.6 | 34.7 ± 3.0 | 33.5 ± 3.2 |
| Sex: Female | | | | |
| 0 | 22.3 ± 1.9 | 23.1 ± 2.5 | 22.1 ± 2.3 | 23.1 ± 3.1 |
| 4 | 25.2 ± 3.1 | 23.9 ± 1.6 | 24.1 ± 1.7 | 24.7 ± 3.2 |
| 8 | 25.7 ± 2.3 | 24.2 ± 1.7 | 24.3 ± 2.0 | 25.3 ± 3.2 |
| 13 | 24.2 ± 1.3 | 22.5 ± 2.2 | 22.6 ± 2.5 | 23.9 ± 3.2 |

Table S2. Summary of Ophthalmological Examinations

| Eye (Bilateral) | No. of animals | Findings | Group / Dose (mg/kg/day) | | | |
|--------------------|-------------------|----------|--------------------------|------------|------------|------------|
| | | | G1 / 0 | G2 / 1,250 | G3 / 2,500 | G4 / 5,000 |
| Sex : Male | | | | | | |
| Pupil light reflex | 5 | Normal | 5 | 5 | 5 | 5 |
| Anterior segment | 5 | Normal | 5 | 5 | 5 | 5 |
| Transparent media | 5 | Normal | 5 | 5 | 5 | 5 |
| Fundus | 5 | Normal | 5 | 5 | 5 | 5 |
| Sex: Female | | | | | | |
| Pupil light reflex | 5 | Normal | 5 | 5 | 5 | 5 |
| Anterior segment | 5 | Normal | 5 | 5 | 5 | 5 |
| Transparent media | 5 | Normal | 5 | 5 | 5 | 5 |
| Fundus | 5 | Normal | 5 | 5 | 5 | 5 |

Table S3. Summary of Urinalysis Results

| Urinalysis parameters | | Group / Dose (mg/kg/day) | | | |
|-----------------------|-------------|--------------------------|------------|------------|------------|
| | | G1 / 0 | G2 / 1,250 | G3 / 2,500 | G4 / 5,000 |
| No. of animals | | 5 | 5 | 5 | 5 |
| Sex : Male | | | | | |
| Volume (mL) | | 12.5 ± 3 | 14.0 ± 7 | 11.8 ± 6 | 15.7 ± 6 |
| Color | Pale yellow | 3 | - | - | - |
| | Yellow | 2 | 5 | 5 | 5 |
| | Amber | - | - | - | - |
| Transparency | Clear | 5 | 5 | 5 | 5 |
| pH | 7 | 2 | - | - | - |
| | 8 | 3 | 5 | 5 | 4 |
| | 9 | - | - | - | 1 |
| Protein (mg/dL) | - | 2 | 2 | 4 | 3 |
| | 25 | 2 | 2 | 1 | 2 |
| | 75 | 1 | 1 | - | - |
| | 150 | - | - | - | - |
| | 500 | - | - | - | - |
| Glucose (mg/dL) | Normal | 5 | 5 | 5 | 5 |
| Ketone body (mg/dL) | - | 2 | - | - | - |
| | 5 | 3 | 4 | 4 | 4 |
| | 15 | - | 1 | 1 | 1 |
| Bilirubin (mg/dL) | - | 5 | 5 | 5 | 5 |
| Occult blood (Ery/μL) | - | 3 | 5 | 5 | 5 |
| | 10 | 2 | - | - | - |
| Cast | 0 | 5 | 5 | 5 | 5 |
| Epithelial cell | 0 | 5 | 5 | 5 | 5 |
| Leukocyte | 0 | 5 | 5 | 5 | 5 |
| Erythrocyte | 0 | 2 | 5 | 5 | 5 |
| | 1~10 | 3 | - | - | - |
| Specific gravity | 1,021~1,030 | - | - | 1 | - |
| | 1,031~1,040 | - | 2 | 1 | - |
| | 1,041~1,050 | 3 | 2 | 1 | 3 |
| | 1,051~1,060 | 1 | - | 3 | 2 |
| | >1,060 | 1 | 1 | - | - |
| Sex : Female | | | | | |
| Volume (mL) | | 5.4 ± 1.6 | 7.2 ± 2.8 | 6.6 ± 5.8 | 9.0 ± 5.2 |
| Color | Pale yellow | | | | |
| | Yellow | 5 | 5 | 4 | 3 |
| | Amber | - | - | 1 | 2 |
| Transparency | Clear | 5 | 5 | 5 | 5 |
| pH | 7 | - | - | - | - |
| | 8 | 5 | 4 | 3 | 5 |
| | 9 | - | 1 | 2 | - |
| Protein (mg/dL) | - | 2 | 3 | 3 | 5 |
| | 25 | 3 | 2 | 2 | - |
| | 75 | - | - | - | - |
| | 150 | - | - | - | - |
| | 500 | - | - | - | - |
| Glucose (mg/dL) | Normal | 5 | 5 | 5 | 5 |
| Ketone body (mg/dL) | - | 1 | - | - | - |
| | 5 | 4 | 4 | 1 | 3 |
| | 15 | - | 1 | 3 | 2 |
| | 50 | - | - | 1 | - |
| Bilirubin (mg/dL) | - | 5 | 5 | 5 | 5 |
| Occult blood (Ery/μL) | - | 5 | 5 | 5 | 5 |
| Cast | 0 | 5 | 5 | 5 | 5 |
| Epithelial cell | 5 | 5 | 5 | 5 | 5 |
| Leukocyte | 0 | 5 | 5 | 5 | 5 |
| Erythrocyte | 0 | 5 | 5 | 5 | 5 |
| | 1~10 | - | - | - | - |
| Specific gravity | 1,021~1,030 | - | - | 1 | 2 |
| | 1,031~1,040 | - | 1 | 1 | - |
| | 1,041~1,050 | 1 | 1 | - | 1 |
| | 1,051~1,060 | 3 | 3 | 1 | 1 |
| | >1,060 | 1 | - | 2 | 1 |

Table S4. Summary of Hematological and Clinical Chemistry Parameters

| Parameter | Group / Dose (mg/kg/day) | | | |
|---------------------------|--------------------------|--------------|---------------|----------------|
| | G1 / 0 | G2 / 1,250 | G3 / 2,500 | G4 / 5,000 |
| No. of animals | 10 | 10 | 10 | 10 |
| Sex : Male | | | | |
| RBC (10 ⁶ /μL) | 8.68 ± 0.4 | 8.76 ± 0.3 | 8.49 ± 0.1 | 8.46 ± 0.3 |
| HGB (g/dL) | 15.9 ± 0.5 | 15.9 ± 0.4 | 15.5 ± 0.4 | 15.4 ± 0.3 * |
| HCT (%) | 44.7 ± 1.3 | 44.8 ± 1.2 | 43.7 ± 0.9 | 43.4 ± 1.1 * |
| MCV (fL) | 51.6 ± 1.9 | 51.1 ± 0.9 | 51.5 ± 1.4 | 51.3 ± 1.4 |
| MCH (pg) | 18.3 ± 0.8 | 18.2 ± 0.4 | 18.3 ± 0.6 | 18.2 ± 0.7 |
| MCHC (g/dL) | 35.5 ± 0.4 | 35.6 ± 0.2 | 35.5 ± 0.4 | 35.4 ± 0.6 |
| PLT (10 ³ /μL) | 1021 ± 81 | 980 ± 72 | 893 ± 132 | 936 ± 148 |
| Reti (%) | 2.87 ± 0.4 | 2.79 ± 0.3 | 3.09 ± 0.36 | 2.91 ± 0.2 |
| WBC (10 ³ /μL) | 9.78 ± 2.3 | 10.01 ± 2.1 | 9.32 ± 1.96 | 8.58 ± 2.0 |
| NEU (%) | 18.3 ± 5.5 | 20.0 ± 8.4 | 20.8 ± 6.9 | 21.3 ± 9.4 |
| LYM (%) | 70.8 ± 6.4 | 68.7 ± 8.7 | 67.6 ± 8.0 | 69.0 ± 9.7 |
| MONO (%) | 8.8 ± 2.0 | 9.7 ± 2.0 | 10.2 ± 2.1 | 8.3 ± 1.4 |
| EOS (%) | 1.8 ± 0.5 | 1.4 ± 0.4 | 1.3 ± 0.6 * | 1.2 ± 0.4 * |
| BASO (%) | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 |
| PT (sec) | 19.3 ± 0.9 | 19.2 ± 0.5 | 19.1 ± 0.7 | 18.9 ± 0.9 |
| APTT (sec) | 15.4 ± 1.1 | 15.9 ± 1.9 | 15.8 ± 1.4 | 15.0 ± 2.3 |
| ALT (U/L) | 24 ± 3.5 | 30.7 ± 9.6 | 27.5 ± 4.1 | 26.7 ± 4.7 |
| AST (U/L) | 69.1 ± 8.4 | 76.1 ± 22.4 | 68.7 ± 8.5 | 73.3 ± 10.7 |
| ALP (U/L) | 245.3 ± 61.7 | 261.7 ± 43.6 | 235.2 ± 49.2 | 248.8 ± 70.5 |
| GGT(U/L) | 0.34 ± 0.1 | 0.37 ± 0.1 | 0.23 ± 0.1 | 0.31 ± 0.2 |
| Glu (mg/dL) | 134 ± 17 | 135 ± 13 | 132 ± 14 | 124 ± 12 |
| BUN (mg/dL) | 11.9 ± 1.2 | 12.1 ± 1.4 | 13.0 ± 2.0 | 12.5 ± 1.2 |
| Crea (mg/dL) | 0.45 ± 0.04 | 0.44 ± 0.05 | 0.46 ± 0.04 | 0.45 ± 0.03 |
| T-bili (mg/dL) | 0.08 ± 0.03 | 0.07 ± 0.03 | 0.06 ± 0.01 | 0.07 ± 0.03 |
| T-Chol (mg/dL) | 76 ± 15 | 93 ± 25 | 71 ± 16 | 80 ± 25 |
| TG (mg/dL) | 72 ± 20 | 82 ± 38 | 71 ± 31 | 74 ± 50 |
| TP (g/dL) | 5.8 ± 0.2 | 6.0 ± 0.2 | 5.9 ± 0.2 | 6.0 ± 0.3 |
| Alb (g/dL) | 2.3 ± 0.1 | 2.4 ± 0.1 | 2.3 ± 0.1 | 2.4 ± 0.1 |
| A/G ratio | 0.66 ± 0.1 | 0.66 ± 0.04 | 0.64 ± 0.04 | 0.65 ± 0.04 |
| P (mg/dL) | 5.62 ± 0.4 | 5.44 ± 0.6 | 5.69 ± 0.3 | 6.15 ± 0.44 * |
| Ca (mg/dL) | 9.9 ± 0.4 | 10.2 ± 0.4 | 10.2 ± 0.3 | 10.1 ± 0.3 |
| Na (mmol/L) | 139.1 ± 1.5 | 138.6 ± 0.7 | 138.5 ± 1.3 | 137.5 ± 2 |
| K (mmol/L) | 3.89 ± 0.2 | 3.95 ± 0.2 | 3.78 ± 0.2 | 3.87 ± 0.15 |
| Cl (mmol/L) | 107.8 ± 1.7 | 106.8 ± 0.8 | 106.9 ± 1.6 | 105.5 ± 2.1 ** |
| Sex: Female | | | | |
| RBC (10 ⁶ /μL) | 8.19 ± 0.5 | 8.21 ± 0.4 | 7.71 ± 0.55 * | 7.94 ± 0.3 |
| HGB (g/dL) | 15.6 ± 0.8 | 15.8 ± 0.4 | 15.4 ± 0.5 | 15.3 ± 0.6 |
| HCT (%) | 42.8 ± 2.1 | 43.6 ± 1.1 | 42.4 ± 1.2 | 42.4 ± 1.4 |
| MCV (fL) | 52.3 ± 1.2 | 53.2 ± 1.6 | 55.1 ± 3.0 # | 53.4 ± 1.2 |
| MCH (pg) | 19.0 ± 0.5 | 19.3 ± 0.6 | 20.0 ± 0.9 ** | 19.3 ± 0.6 |
| MCHC (g/dL) | 36.3 ± 0.2 | 36.2 ± 0.2 | 36.3 ± 0.4 | 36.2 ± 0.6 |
| PLT (10 ³ /μL) | 901 ± 30 | 928 ± 62 | 903 ± 165 | 890 ± 99 |
| Reti (%) | 2.55 ± 0.3 | 2.37 ± 0.4 | 3.54 ± 2.4 | 2.28 ± 0.4 |
| WBC (10 ³ /μL) | 5.78 ± 3.3 | 5.15 ± 1.1 | 5.22 ± 1.2 | 4.70 ± 1.9 |
| NEU (%) | 19.8 ± 5.4 | 17.0 ± 6.9 | 14.5 ± 6.9 | 18.2 ± 4.6 |
| LYM (%) | 69.7 ± 7.0 | 73.3 ± 7.2 | 76.6 ± 7.7 | 71.4 ± 5.1 |
| MONO (%) | 8.4 ± 1.7 | 8.0 ± 1.8 | 7.4 ± 2.1 | 8.4 ± 0.8 |
| EOS (%) | 1.8 ± 0.6 | 1.4 ± 0.4 | 1.2 ± 0.6 | 1.7 ± 0.7 |
| BASO (%) | 0.3 ± 0.2 | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| PT (sec) | 18.1 ± 0.8 | 18.6 ± 0.7 | 18.6 ± 0.9 | 19.0 ± 1.0 |
| APTT (sec) | 16.0 ± 0.8 | 15.0 ± 1.7 | 15.5 ± 0.9 | 15.4 ± 0.7 |
| ALT (U/L) | 26.2 ± 9.5 | 24.8 ± 7.0 | 20.7 ± 4.1 | 20.8 ± 4.8 |
| AST (U/L) | 64.9 ± 14.3 | 63.6 ± 11.6 | 65.1 ± 13.2 | 60.3 ± 11.9 |
| ALP (U/L) | 134 ± 35.5 | 128.7 ± 40.8 | 126.2 ± 47.2 | 113.2 ± 41.3 |
| GGT(U/L) | 0.53 ± 0.3 | 0.47 ± 0.2 | 0.52 ± 0.3 | 0.56 ± 0.24 |
| Glu (mg/dL) | 133 ± 12 | 126 ± 16 | 128 ± 22 | 122 ± 13 |
| BUN (mg/dL) | 11.7 ± 1.8 | 12.6 ± 1.9 | 11.9 ± 2.4 | 11.8 ± 2.1 |
| Crea (mg/dL) | 0.52 ± 0.04 | 0.53 ± 0.07 | 0.51 ± 0.05 | 0.47 ± 0.05 |
| T-bili (mg/dL) | 0.09 ± 0.03 | 0.10 ± 0.02 | 0.10 ± 0.03 | 0.07 ± 0.02 |

| | | | | |
|----------------|-------------|-------------|---------------|---------------|
| T-Chol (mg/dL) | 102 ± 11 | 94 ± 13 | 85 ± 14 * | 82 ± 19 * |
| TG (mg/dL) | 26 ± 22 | 16 ± 8 | 18 ± 4 | 20 ± 8 |
| TP (g/dL) | 6.4 ± 0.5 | 6.1 ± 0.4 | 6.1 ± 0.3 | 6.1 ± 0.4 |
| Alb (g/dL) | 2.9 ± 0.3 | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.7 ± 0.2 |
| A/G ratio | 0.82 ± 0.1 | 0.79 ± 0.05 | 0.79 ± 0.07 | 0.79 ± 0.06 |
| P (mg/dL) | 4.05 ± 0.9 | 4.80 ± 0.9 | 4.64 ± 0.7 | 4.73 ± 0.6 |
| Ca (mg/dL) | 9.9 ± 0.7 | 9.9 ± 0.3 | 9.9 ± 0.3 | 9.7 ± 0.3 |
| Na (mmol/L) | 138.7 ± 1.0 | 138.6 ± 0.8 | 139.1 ± 1.1 | 137.6 ± 1.0 * |
| K (mmol/L) | 3.62 ± 0.2 | 3.71 ± 0.3 | 3.70 ± 0.3 | 3.81 ± 0.3 |
| Cl (mmol/L) | 107.8 ± 1.4 | 107.7 ± 0.7 | 109.2 ± 1.0 * | 107.7 ± 1.1 |

Significantly different from control by Dunnett's t-test : * p<0.05, **p<0.01

Significantly different from control by Steel test : # p<0.05

Table S5. Summary of Mean Absolute Organ Weights

| Week | Group / Dose (mg/kg/day) | | | |
|-------------------------|--------------------------|-----------------|-----------------|-----------------|
| | G1 / 0 | G2 / 1,250 | G3 / 2,500 | G4 / 5,000 |
| Organ weight (g) | | | | |
| Sex :Male | | | | |
| Body weight | 590.8 ± 62.1 | 586.2 ± 70.3 | 611.8 ± 63.3 | 576.0 ± 46.5 |
| Brain | 2.21 ± 0.05 | 2.17 ± 0.08 | 2.23 ± 0.05 | 2.17 ± 0.04 |
| Pituitary gland | 0.0135 ± 0.0016 | 0.0126 ± 0.0020 | 0.0123 ± 0.0015 | 0.0134 ± 0.0021 |
| Heart | 1.68 ± 0.17 | 1.65 ± 0.18 | 1.64 ± 0.12 | 1.60 ± 0.15 |
| Lung | 1.77 ± 0.16 | 1.73 ± 0.19 | 1.79 ± 0.12 | 1.72 ± 0.19 |
| Liver | 14.96 ± 1.48 | 16.03 ± 2.86 | 16.63 ± 2.80 | 16.71 ± 2.34 |
| Spleen | 0.92 ± 0.16 | 0.87 ± 0.12 | 0.99 ± 0.19 | 0.86 ± 0.11 |
| Kidney | 3.40 ± 0.22 | 3.54 ± 0.39 | 3.62 ± 0.27 | 3.74 ± 0.28 |
| Adrenal gland | 0.0679 ± 0.00857 | 0.0682 ± 0.0070 | 0.0618 ± 0.0084 | 0.0632 ± 0.0070 |
| Testis | 3.45 ± 0.73 | 3.68 ± 0.36 | 3.56 ± 0.61 | 3.66 ± 0.37 |
| Prostate | 0.71 ± 0.12 | 0.73 ± 0.17 | 0.63 ± 0.16 | 0.67 ± 0.12 |
| Organ weight (g) | | | | |
| Sex: Female | | | | |
| Body weight | 326.0 ± 33.3 | 304.8 ± 21.0 | 299.3 ± 29.2 | 309.3 ± 40.0 |
| Brain | 1.97 ± 0.06 | 1.98 ± 0.09 | 1.98 ± 0.10 | 2.02 ± 0.13 |
| Pituitary gland | 0.0187 ± 0.0055 | 0.0184 ± 0.0031 | 0.0174 ± 0.0039 | 0.0168 ± 0.0022 |
| Heart | 1.04 ± 0.08 | 0.97 ± 0.08 | 0.97 ± 0.07 | 0.99 ± 0.10 |
| Lung | 1.27 ± 0.08 | 1.26 ± 0.05 | 1.24 ± 0.13 | 1.29 ± 0.12 |
| Liver | 8.31 ± 0.75 | 7.48 ± 0.49 | 7.85 ± 0.76 | 7.97 ± 1.12 |
| Spleen | 0.60 ± 0.06 | 0.53 ± 0.05 | 0.57 ± 0.07 | 0.57 ± 0.08 |
| Kidney | 1.97 ± 0.18 | 1.89 ± 0.15 | 1.92 ± 0.15 | 2.11 ± 0.29 |
| Adrenal gland | 0.0706 ± 0.0154 | 0.0642 ± 0.0117 | 0.0728 ± 0.0085 | 0.0692 ± 0.0077 |
| Ovary | 0.0877 ± 0.0149 | 0.0812 ± 0.0229 | 0.0991 ± 0.0094 | 0.0909 ± 0.0185 |
| Uterus | 0.58 ± 0.21 | 0.66 ± 0.18 | 0.66 ± 0.26 | 0.55 ± 0.11 |

Table S6. Result of Main Study in Male ICR Mice

| Group | Dose | Route | Hours after dosing | Animal ID | PCE / (PCE+NCE) | MNPCE / PCE |
|---|-------|-------|--------------------|--------------------|-----------------|-------------------|
| Negative control (Water for injection) | 0 | P.O. | 24 | 1101 | 149 / 500 | 0 / 4,000 |
| | | | | 1102 | 149 / 500 | 2 / 4,000 |
| | | | | 1103 | 143 / 500 | 2 / 4,000 |
| | | | | 1104 | 146 / 500 | 3 / 4,000 |
| | | | | 1105 | 150 / 500 | 1 / 4,000 |
| | | | | Total | 737 / 2,500 | 8 / 20,000 |
| | | | | %(Mean \pm S.D.) | 29.5 \pm 0.58 | 0.040 \pm 0.029 |
| Test Substance (KP-1) | 1,250 | P.O. | 24 | 1201 | 152 / 500 | 3 / 4,000 |
| | | | | 1202 | 148 / 500 | 2 / 4,000 |
| | | | | 1203 | 146 / 500 | 2 / 4,000 |
| | | | | 1204 | 155 / 500 | 0 / 4,000 |
| | | | | 1205 | 154 / 500 | 1 / 4,000 |
| | | | | Total | 755 / 2,500 | 8 / 20,000 |
| | | | | %(Mean \pm S.D.) | 30.2 \pm 0.77 | 0.040 \pm 0.029 |
| | 2,500 | P.O. | 24 | 1301 | 145 / 500 | 0 / 4,000 |
| | | | | 1302 | 157 / 500 | 2 / 4,000 |
| | | | | 1303 | 158 / 500 | 2 / 4,000 |
| | | | | 1304 | 152 / 500 | 3 / 4,000 |
| | | | | 1305 | 161 / 500 | 2 / 4,000 |
| | | | | Total | 773 / 2,500 | 9 / 20,000 |
| | | | | %(Mean \pm S.D.) | 30.9 \pm 1.25 | 0.045 \pm 0.027 |
| Positive Control (MMC) | 5,000 | P.O. | 24 | 1401 | 144 / 500 | 1 / 4,000 |
| | | | | 1402 | 139 / 500 | 1 / 4,000 |
| | | | | 1403 | 144 / 500 | 1 / 4,000 |
| | | | | 1404 | 148 / 500 | 2 / 4,000 |
| | | | | 1405 | 150 / 500 | 1 / 4,000 |
| | | | | Total | 725 / 2,500 | 6 / 20,000 |
| | | | | %(Mean \pm S.D.) | 29.0 \pm 0.85 | 0.030 \pm 0.011 |
| | 2 | I.P. | 24 | 1501 | 168 / 500 | 286 / 4,000 |
| | | | | 1502 | 171 / 500 | 251 / 4,000 |
| | | | | 1503 | 153 / 500 | 244 / 4,000 |
| | | | | 1504 | 164 / 500 | 218 / 4,000 |
| | | | | 1505 | 179 / 500 | 256 / 4,000 |
| | | | | Total | 835** / 2,500 | 1,255## / 20,000 |
| | | | | %(Mean \pm S.D.) | 33.4 \pm 1.91 | 6.275 \pm 0.611 |

P.O.: Per Os, I.P.: Intraperitoneal, MNPCE: Micronucleated polychromatic erythrocyte,
PCE: Polychromatic erythrocyte, NCE: Normochromatic erythrocyte, MMC: Mitomycin C
Significantly different from control by Aspin-Welch t-test : ** p<0.01,
Significantly different from control by Mann-Whiney test : ## p<0.01

Table S7. Summary of Micronucleus Test

| Historical control values of MNPCE | | | | | | | |
|---|-------------------------|--------------|----|-----------------------------------|--------------------------------------|-------|---|
| Group | Hours after dosing (hr) | Dose (mg/kg) | N | MNPCE / PCE (%) (Mean \pm S.D.) | Range ¹ [MNPCE / PCE] (%) | | 95 % control limit [MNPCE / PCE] ² |
| | | | | | MIN | MAX | |
| Negative control | 24 | 0 | 32 | 0.042 \pm 0.019 | 0.007 | 0.077 | <13 |
| Positive control | 24 | 2 | 32 | 6.119 \pm 1.275 | 4.988 | 7.250 | - |
| Historical control values of ratio of PCE to total erythrocytes | | | | | | | |
| Group | Hours after dosing (hr) | Dose (mg/kg) | N | MNPCE / PCE (%) (Mean \pm S.D.) | Range [MNPCE / PCE] (%) | | |
| | | | | | MIN | MAX | |
| Negative control | 24 | 0 | 32 | 30.66 \pm 3.006 | 25.96 | 35.36 | |
| Positive control | 24 | 2 | 32 | 29.39 \pm 3.864 | 24.72 | 34.07 | |

Negative control: Water for injection, Normal saline injection, Corn oil, 0.5 % methylcellulose 1500 centripoise solution, 0.5% carboxymethylcellulose sodium salt solution, *etc.*

Positive control: Mitomycin C (2 mg/kg, I.P., single dosing)

¹The range was calculated by the control limit of X derived from X-R value.

²Poisson-based 95 % control limits of the historical negative control data.

Table S8. Summary of Main Study

| Test substance | Dose (µg/mL) | RPD (%) | S9 mix | Trt-Ree time (hr) | No. of cell analyzed | Number of cells with structural aberrations | | | | | | | | | | Number of cells with numerical aberrations | | | Others ¹ |
|---------------------------|-----------------|------------|-----------|----------------------|----------------------------|---|-----|-----|-----|-----|-----|-----|-----------|-----------------|------------|--|--------------|---------|---------------------|
| | | | | | | ctd | csb | cte | cse | frg | gap | | Total (%) | | end | pol | Total (%) | | |
| | | | | | | | | | | | ctg | csg | gap- | gap+ | | | | | |
| Water for injection | 0 | 100 | - | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | 1 (0.3) | 0 | 1 | 1 (0.3) | 0 | |
| | | | | | 150 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 78.1 | 98.1 | - | 6-18 | | not observed | | | | | | | | | | | | | |
| KP-1 | 156 | 96.2 | - | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 0 | 0 (0.0) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 313 | 93.8 | - | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 0 | 0 (0.0) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 625 | 90.3 | - | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 (0.0) | 1 (0.3) | 0 | 0 | 0 (0.0) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | MMC | 0.1 | 58.7 | - | 6-18 | 150 | 13 | 0 | 42 | 0 | 0 | 0 | 0 | 86** (28.7) | 86 (28.7) | 0 | 0 | 0 (0.0) | 0 |
| | | | | | | 150 | 15 | 2 | 40 | 0 | 0 | 2 | 0 | | | 0 | 0 | | |
| Water for injection | | 0 | 100 | + | 6-18 | 150 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 (0.3) | 2 (0.7) | 0 | 0 | 1 (0.3) | 0 |
| 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | | | | | | | | |
| KP-1 | 156 | 87.2 | + | 6-18 | 150 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 (0.3) | 1 (0.3) | 0 | 0 | 1 (0.3) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 1 | | | |
| | 313 | 86.1 | + | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 0 | 0 (0.0) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 625 | 82.1 | + | 6-18 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 0 | 1 (0.3) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 1 | | | |
| | B[a]P | 20 | 51.4 | + | 6-18 | 150 | 10 | 0 | 25 | 1 | 0 | 0 | 0 | 60** (20.0) | 60 (20.0) | 0 | 0 | 0 (0.0) | 0 |
| | | | | | | 150 | 7 | 0 | 28 | 0 | 0 | 2 | 0 | | | 0 | 0 | | |
| Water for injection | 0 | 100 | - | 24-0 | 150 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | 1 (0.3) | 0 | 1 | 1 (0.3) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | 0 |
| | 78.1 | 92.1 | - | 24-0 | | not observed | | | | | | | | | | | | | |
| KP-1 | 156 | 89.7 | - | 24-0 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 0 | 0 (0.0) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 313 | 85.1 | - | 24-0 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | 1 (0.3) | 0 | 1 | 1 (0.3) | 0 | |
| | | | | | 150 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | 625 | 79.6 | - | 24-0 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 | 1 | 1 (0.3) | 0 | |
| | | | | | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | |
| | MMC | 0.1 | 52.6 | - | 24-0 | 150 | 25 | 0 | 60 | 0 | 0 | 0 | 0 | 125** (41.7) | 125 (41.7) | 0 | 0 | 0 (0.0) | 0 |
| | | | | | | 150 | 21 | 1 | 52 | 0 | 0 | 6 | 0 | | | 0 | 0 | | |

Aberration: ctg: chromatid gap, csg: chromosome gap, ctb: chromatid break, cte: chromatid exchange, csb: chromosome break, cse: chromosome exchange, frg: fragmentation, end: endoreduplication, pol: polyploidy

MMC: Mitomycin C, B[a]P: Benzo[a]pyrene, RPD: Relative Population Doubling, Trt-Rec time: Treatment-Recovery times, gap-: Total number of cells with structural aberrations excluding gap, gap+: Total number of cells with structural aberrations including gap

¹Other were excluded from the number of cells with chromosomal aberrations.

Significant difference from negative control by Fisher's exact test: ** p<0.01 #: precipitation

Table S9. Historical Control Data

| Historical control values of structural aberrations | | | | | | | | |
|---|--------|-------------------|----|---|-----------|--------|---|-----|
| Group | S9 mix | Trt-Rec time (hr) | N | Structural aberration cells excluding gap (%) (Mean \pm S.D.) | Range (%) | | 95 % control limit ³ [Structural aberration cells/300 cells] | |
| | | | | | MIN | MAX | MIN | MAX |
| Negative | - | 6-18 | 44 | 0.288 \pm 0.364 | 0 | 1.01* | 0 | <3 |
| | + | 6-18 | 44 | 0.311 \pm 0.390 | 0 | 1.09* | 0 | <3 |
| | - | 24-0 | 42 | 0.246 \pm 0.361 | 0 | 0.87* | 0 | <2 |
| Positive | - | 6-18 ¹ | 39 | 23.44 \pm 5.667 | 11.09* | 35.78* | | |
| | + | 6-18 ² | 39 | 24.64 \pm 4.922 | 12.13* | 37.15* | | |
| | - | 24-0 ¹ | 37 | 35.37 \pm 6.862 | 19.09* | 51.65* | | |
| Historical control values of ratio of PCE to total erythrocytes | | | | | | | | |
| Group | S9 mix | Trt-Rec time (hr) | N | Numerical aberration cells (%) (Mean \pm S.D.) | Range (%) | | 95 % control limit ³ [Structural aberration cells/300 cells] | |
| | | | | | MIN | MAX | MIN | MAX |
| Negative | - | 6-18 | 44 | 0.174 \pm 0.292 | 0 | 0.83* | 0 | <2 |
| | + | 6-18 | 44 | 0.167 \pm 0.264 | 0 | 0.97* | 0 | <2 |
| | - | 24-0 | 42 | 0.262 \pm 0.290 | 0 | 1.13* | 0 | <2 |

Negative control: Water for injection, Dimethyl sulfoxide, Acetone,

Trt-Rex time: Treatment-Recovery times

¹Mitomycin C (0.1 μ g/mL), ²Benzo[a]pyrene (20 μ g/mL), ³Poisson-based 95 % control limits of the historical negative control data.

N: The total number of chromosome aberration test

The above historical control values were obtained from the data pooled from Jul. 15, 2013 to May 22, 2017.

*The range was calculated by the control limit of X derived from X-R-Rs value.